RecruitingNCT06001528

Serum and Tissue Metabolite-based Prediction of Sentinel Lymph Node Metastasis in Breast Cancer


Sponsor

Shantou Central Hospital

Enrollment

2,400 participants

Start Date

Jan 1, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

Breast cancer is a malignant tumor with the highest morbidity and mortality among women worldwide. Accurate staging of axillary lymph nodes is critical for metastatic assessment and decisions regarding treatment modalities in breast cancer patient. Among patients who underwent sentinel lymph node biopsy, about 70 % of the patients had negative pathological results and in other words, these 70 % of the patients received unnecessary surgery. At present, imaging and pathological diagnosis is the main measure of lymph node metastasis in breast cancer. However, limitations remained. Artificial intelligence, including deep learning and machine learning algorithms, has emerged as a possible technique, which can make a more accuracy prediction through machine-based collection, learning and processing of previous information, especially in radiology and pathology-based diagnosis. With the intensification of the concept of precision medicine and the development of non-invasive technology, the investigators intend to use the artificial intelligence technology to develop a serum and tissue-based predictive model for sentinel lymph node metastasis diagnosis combined with imaging and pathological information, providing specific, efficient and non-invasive biological indicators for the monitoring and early intervention of lymph node metastasis in patient with breast cancer. Therefore, the investigators retrospectively include serum samples from early breast cancer patients undergoing sentinel lymph node biopsy, including a discovery cohort and a modeling cohort. Metabolites were detected and screened in the discovery cohort and then as the target metabolites for targeted detection in the modeling cohort. Combined with preoperative imaging and pathological information, a prediction model of breast cancer sentinel lymph node metastasis based on serum metabolites would be established. Subsequently, multi-center breast cancer patients will prospectively be included to verify the accuracy and stability of the model.


Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study collects blood and tissue samples from breast cancer patients before and after surgery to identify metabolic markers (chemical patterns in the body) that can predict whether cancer has spread to the sentinel lymph nodes — the first lymph nodes near the tumor that cancer typically reaches. **You may be eligible if...** - You have been diagnosed with breast cancer (confirmed by pathology) - You have not had any chemotherapy or hormone therapy before surgery - Your cancer has not spread to distant organs - You are having a mastectomy or breast-conserving surgery that includes a sentinel lymph node biopsy - You agree to provide a blood sample before surgery and allow access to your imaging and pathology data **You may NOT be eligible if...** - You have already received neoadjuvant (pre-surgery) therapy - Your cancer has spread to distant sites at the time of diagnosis - You have another primary cancer or bilateral (both sides) breast cancer - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Shantou Central Hospital

Shantou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06001528


Related Trials